The genetic understanding of cancer has led to enhanced individual risk assessment, improved screening guidelines, and improved outcomes based on cancer prevention, early detection, and, in some cases, targeted therapy. Huntsman Cancer Institute (HCI) is positioned to make exceptional contributions in this individualized oncology arena. HCI has a unique research resource to support genetic and population studies, the Utah Population Database (UPDB), a compelling history of genetic discovery in oncology, and a strategic plan to accelerate translational advances from this platform. We have forged an alliance with Intermountain Healthcare, a nationally acclaimed Utah health network, linking data for more than 80-85 percent of the cancer patients in our State to the UPDB, enabling the entire population of Utah to comprise a cancer research laboratory for genetic, population, and outcomes research. Utah is home to seven Native American tribes or nations as well as extensive rural and frontier populations that have poor cancer outcomes.
We aim to serve as a national research resource for addressing the needs of these underserved populations to improve cancer prevention and care. HCI research is organized into five Programs that provide an environment of cancer focus, transdisciplinary exchange, and collaboration: Nuclear Control of Cell Growth and Differentiation;Cell Response and Regulation;Imaging, Diagnostics, and Therapeutics;Gastrointestinal Cancers;and Cancer Control and Population Sciences. These Programs integrate the activities of 133 members who have $45 million in extramural grant support, with more than $17 million in NCI direct costs. Cancer-focused research during the current award period is documented in 1,374 unique publications, of which 26 percent are collaborative with one or more Cancer Center members. Thirteen Cancer Center Shared Resources support our scientists, providing access to specialized instrumentation, assays, services, research materials, and expert consultation and collaboration. We request funds to support Years 21-25 of our Cancer Center Support Grant (CCSG). A new Executive Director, Mary Beckerle, Ph.D., was appointed in August 2006. Under her leadership, HCI has developed a plan to guide the next five years, including expansion of HCI's cancer specialty hospital, expansion of HCI's genetic platform for pre-clinical studies, development of a Center for Investigational Therapeutics (including a Phase I program), and expansion of population science (including epidemiological and behavioral research) to impact care of cancer survivors and reduce health disparities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA042014-23
Application #
8253782
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-05-09
Project End
2015-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
23
Fiscal Year
2012
Total Cost
$1,454,512
Indirect Cost
$488,059
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Albright, Frederick; Stephenson, Robert A; Agarwal, Neeraj et al. (2015) Prostate cancer risk prediction based on complete prostate cancer family history. Prostate 75:390-8
Eiring, A M; Page, B D G; Kraft, I L et al. (2015) Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 29:586-97
Lerman, Daniel M; Monument, Michael J; McIlvaine, Elizabeth et al. (2015) Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 62:759-65
Quackenbush, John F; Cassidy, Pamela B; Pfeffer, Lawrence M et al. (2014) Isolation of circulating microRNAs from microvesicles found in human plasma. Methods Mol Biol 1102:641-53
Clark, Kathleen A; Graves, Barbara J (2014) Dual views of SRF: a genomic exposure. Genes Dev 28:926-8
Zhang, Rui; Yang, Jiyuan; Sima, Monika et al. (2014) Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc Natl Acad Sci U S A 111:12181-6
Oakley, Gretchen M; Curtin, Karen; Layfield, Lester et al. (2014) Increased melanoma risk in individuals with papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg 140:423-7
Van Vranken, Jonathan G; Bricker, Daniel K; Dephoure, Noah et al. (2014) SDHAF4 promotes mitochondrial succinate dehydrogenase activity and prevents neurodegeneration. Cell Metab 20:241-52
Smith, M A; Hoffman, L M; Beckerle, M C (2014) LIM proteins in actin cytoskeleton mechanoresponse. Trends Cell Biol 24:575-83
Monument, Michael J; Johnson, Kirsten M; McIlvaine, Elizabeth et al. (2014) Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group. PLoS One 9:e104378

Showing the most recent 10 out of 805 publications